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 Abstract – Automated manufacture of liquid filled 
hard gelatine capsules is dependant on the physical 
properties of a pharmaceutical formulation. Here, we 
investigated the performance of a novel formulation 
(phase I clinical trial) for automated capsule filling. 
 
INTRODUCTION 
 Liquid filled hard gelatine capsules can increase oral 
absorption of active pharmaceutical ingredients (API) 
due to poor aqueous solubility [1]. Formulation 
development requires a balancing act of accommodating 
many factors such as the compatibility of excipients with 
the API as well as the hard gelatine capsule, target dose 
or dose range, capsule size and suitable physical 
properties of the formulation for automated capsule 
filling. Formulation development for oral dosing of a 
novel cytotoxic API in a phase I clinical trial setting was 
based on covering a dosing range from 5 to 60mg in 
single dose units using two formulations. Due to 
containment issues associated with cytotoxic drug 
powder and poor aqueous solubility of the API, a liquid 
or semisolid formulation was sought, with the scope to 
scale-up to batch sizes of up to 1000 capsules. The 
performance of two formulations, 2.5% w/w API in 
PEG300 (covering the dose range of 5-30mg) and 10% 
w/w API in PEG300 (covering the dose range from 30-
60mg), was characterised in relation to their physical 
properties and the uniformity of capsule weights. 
 
MATERIALS AND METHODS 
 Kinematic viscosity of formulations and PEG 300 
only (for comparison only) was measured using a BS/U 
Tube Viscometer Size E and F, respectively. 
Measurements were performed at 21qC (n = 7). 
Formulation density was measured using an Anton 
PAAR DMA 48 density meter. Measurements were 
performed at 20qC. Dynamic viscosity was calculated 
using the kinematic viscosity value and the formulation 
density. Size 0 hard gelatine Licaps were filled using the 
CFS1000 (Capsugel) with batch sizes of 900 capsules. 
QC samples of 20 capsules were taken after 100, 250, 
500 and 800 filled capsules and weighed subsequently. 
 
RESULTS AND DISCUSSION 
 Density and Kinematic viscosity values are 
tabulated below (Table 1), with the dynamic viscosity of 
PEG300 only and 2.5% formulation showing similar low 
values and the 10% formulation showing a 4.4 fold 
increase in viscosity. 
 Uniformity of capsule weights of the high strength 
formulation was very good. QC sample 1-3 showed 
deviations of only 0.63-1.2% from the average capsule 
mass. The maximum deviation was recorded in the last 
QC sample with only one capsule mass deviating by 
5.78%. The capsule masses filled with the low strength 
formulation deviated between 9.2-17.8% for all four QC 
samples. However, this deviation still meets the EP 
requirement for immediate release oral dosage forms 
since no more than 2 capsules deviated by more than 
7.5%. 
The observed relationship of dosing accuracy and 
rheological properties has previously been described in 
the literature [2]. 
Table 1. Physical properties of PEG300 only and 2.5% w/w AT13148 - 
P300 and 10% w/w AT13148 - P300. 
 P300 2.5% w/w 
API, P300 
10% w/w 
API, P300 
Density 
(g/cm3) 1.1266 1.1327 1.1522 
Kinematic 
viscosity 
(mm2/s) 
60.71±0.33 74.89±0.55 261.16±3.55 
Dynamic 
viscosity (cP, 
g/(s*cm)) 
69 85 301 
 
Fig. 1. Deviations from average capsule mass for low and high strength 
formulations throughout small scale batch manufacture. 
 
CONCLUSIONS 
 Both formulations performed well on the CFS1000 
and meet EP requirements for uniformity of capsule 
mass. The dosing accuracy of the low viscosity (85cP, 
21qC) formulation is high and can cause dosing 
inaccuracies. However, the low strength formulation still 
meets EP specification. Higher viscosity formulations 
(10% w/w formulation, 300cP, 21qC) are related to high 
dosing accuracy. 
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